News for Healthier Living

Study: FDA Regulation of Abortion Drug Mifepristone from 2011 to 2023 Shaped by Evidence and Caution

An analysis of internal Food and Drug Administration documents by researchers at the Johns Hopkins Bloomberg School of Public Health finds that the agency generally followed cautious and evidence-based recommendations from staff scientists regulating the abortion drug mifepristone over a critical 12-year period.

January 12, 2026


January 14 2026

January 13 2026

January 12 2026

January 11 2026

January 10 2026

January 9 2026

January 8 2026

January 7 2026

January 6 2026

January 5 2026

January 4 2026

January 3 2026

January 2 2026

January 1 2026

December 31 2025